These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 37058012)

  • 21. Roxadustat: Do we know all the answers?
    Li QY; Xiong QW; Yao X; Liu F; Tang X; Fu H; Tong T; Mao J; Peng WX
    Biomol Biomed; 2023 May; 23(3):354-363. PubMed ID: 36724056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic Effect of Roxadustat on Patients With Posttransplant Anemia.
    Miki K; Nakamura Y; Yokoyama T; Kamiyama M; Ishii Y
    Transplant Proc; 2022 Apr; 54(3):671-677. PubMed ID: 35256197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of roxadustat in chronic kidney disease patients complicated with anemia.
    Liu J; Yang F; Waheed Y; Li S; Liu K; Zhou X
    Korean J Intern Med; 2023 Mar; 38(2):147-156. PubMed ID: 36588451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy and safety of roxadustat for anemia in patients with chronic kidney disease: a meta-analysis.
    Zheng Q; Yang H; Fu X; Huang Y; Wei R; Wang Y; Liu YN; Liu WJ
    Nephrol Dial Transplant; 2021 Aug; 36(9):1603-1615. PubMed ID: 33051677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Roxadustat for the treatment of anemia in patients with chronic kidney diseases: a meta-analysis.
    Zhang L; Hou J; Li J; Su SS; Xue S
    Aging (Albany NY); 2021 Jun; 13(13):17914-17929. PubMed ID: 34115611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An evaluation of roxadustat for the treatment of anemia associated with chronic kidney disease.
    Kurata Y; Tanaka T; Nangaku M
    Expert Opin Pharmacother; 2022 Jan; 23(1):19-28. PubMed ID: 34686069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Roxadustat (FG-4592) treatment for anemia in dialysis-dependent (DD) and not dialysis-dependent (NDD) chronic kidney disease patients: A systematic review and meta-analysis.
    Liu J; Zhang A; Hayden JC; Bhagavathula AS; Alshehhi F; Rinaldi G; Kontogiannis V; Rahmani J
    Pharmacol Res; 2020 May; 155():104747. PubMed ID: 32171893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS).
    Shutov E; Sułowicz W; Esposito C; Tataradze A; Andric B; Reusch M; Valluri U; Dimkovic N
    Nephrol Dial Transplant; 2021 Aug; 36(9):1629-1639. PubMed ID: 33630072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients.
    Akizawa T; Yamaguchi Y; Majikawa Y; Reusch M
    Ther Apher Dial; 2021 Oct; 25(5):575-585. PubMed ID: 33200512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Red blood cell lifespan in long-term hemodialysis patients treated with roxadustat or recombinant human erythropoietin.
    Yang X; Zhao B; Wang J; Wang L; Tao M; Lu J; Lin J; Sun J; Wang R
    Ren Fail; 2021 Dec; 43(1):1428-1436. PubMed ID: 34657570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Whether Prolyl Hydroxylase Blocker-Roxadustat-In the Treatment of Anemia in Patients with Chronic Kidney Disease Is the Future?
    Grzeszczak W; Szczyra D; Śnit M
    Int J Environ Res Public Health; 2021 Feb; 18(4):. PubMed ID: 33567688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Roxadustat (Evrenzo
    Ugawa T; Ashizaki M; Murata A; Majikawa Y
    Nihon Yakurigaku Zasshi; 2021; 156(3):187-197. PubMed ID: 33952849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES).
    Csiky B; Schömig M; Esposito C; Barratt J; Reusch M; Valluri U; Sulowicz W
    Adv Ther; 2021 Oct; 38(10):5361-5380. PubMed ID: 34537926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrated proteomic and metabolomic profiling of urine of renal anemia patients uncovers the molecular mechanisms of roxadustat.
    You X; Guo B; Wang Z; Ma H; Liu L; Zhou R; Zheng Y; Zhang X
    Mol Omics; 2023 Jul; 19(6):473-483. PubMed ID: 37039271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A New Approach to the Management of Anemia in CKD Patients: A Review on Roxadustat.
    Becker K; Saad M
    Adv Ther; 2017 Apr; 34(4):848-853. PubMed ID: 28290095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.
    Chen N; Qian J; Chen J; Yu X; Mei C; Hao C; Jiang G; Lin H; Zhang X; Zuo L; He Q; Fu P; Li X; Ni D; Hemmerich S; Liu C; Szczech L; Besarab A; Neff TB; Peony Yu KH; Valone FH
    Nephrol Dial Transplant; 2017 Aug; 32(8):1373-1386. PubMed ID: 28371815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Roxadustat in the treatment of anaemia in chronic kidney disease.
    Del Vecchio L; Locatelli F
    Expert Opin Investig Drugs; 2018 Jan; 27(1):125-133. PubMed ID: 29254377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients.
    Akizawa T; Tanaka-Amino K; Otsuka T; Yamaguchi Y
    Am J Nephrol; 2021; 52(9):702-713. PubMed ID: 34628408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of roxadustat for anaemia in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: A systematic review and meta-analysis.
    Zheng L; Tian J; Liu D; Zhao Y; Fang X; Zhang Y; Liu Y
    Br J Clin Pharmacol; 2022 Mar; 88(3):919-932. PubMed ID: 34428860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.
    Barratt J; Dellanna F; Portoles J; Choukroun G; De Nicola L; Young J; Dimković N; Reusch M
    Adv Ther; 2023 Apr; 40(4):1546-1559. PubMed ID: 36749544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.